We serve Chemical Name:4-(hydroxymethyl)-2,6-dimethylphenol CAS:4397-14-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(hydroxymethyl)-2,6-dimethylphenol
CAS.NO:4397-14-2
Synonyms:4-Hydroxy-3,5-dimethyl-benzenemethanol;3,5-dimethyl-4-hydroxy-benzyl alcohol;2,6-dimethyl-4-hydroxymethylphenol;4-hydroxy-3,5-dimethyl-benzyl alcohol
Molecular Formula:C9H12O2
Molecular Weight:152.19000
HS Code:2907299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:293.8ºC at 760 mmHg
Density:1.133g/cm3
Index of Refraction:1.573
PSA:40.46000
Exact Mass:152.08400
LogP:1.50130
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Hydroxy-3,5-dimethyl-benzenemethanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-hydroxy-3,5-dimethyl-benzyl alcohol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Hydroxy-3,5-dimethyl-benzenemethanol Use and application,3,5-dimethyl-4-hydroxy-benzyl alcohol technical grade,usp/ep/jp grade.
Related News: The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 4-(hydroxymethyl)-2,6-dimethylphenol manufacturer The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development. 4-(hydroxymethyl)-2,6-dimethylphenol supplier The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 4-(hydroxymethyl)-2,6-dimethylphenol vendor European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market. 4-(hydroxymethyl)-2,6-dimethylphenol factory A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting.
